{"id":50607,"date":"2025-12-13T22:17:14","date_gmt":"2025-12-13T14:17:14","guid":{"rendered":"https:\/\/flcube.com\/?p=50607"},"modified":"2025-12-13T22:17:16","modified_gmt":"2025-12-13T14:17:16","slug":"sino-biopharms-culmerciclib-wins-nmpa-approval-as-first-cdk2-4-6-inhibitor-for-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50607","title":{"rendered":"Sino Biopharm\u2019s Culmerciclib Wins NMPA Approval as First CDK2\/4\/6 Inhibitor for Breast Cancer"},"content":{"rendered":"\n

Sino Biopharmaceutical (HKG: 1177<\/a>)<\/strong> announced that Culmerciclib Capsules<\/strong>, the world\u2019s first CDK2\/4\/6 inhibitor<\/strong>, received marketing approval from China\u2019s National Medical Products Administration (NMPA) for use with fulvestrant in HR+\/HER2\u2011 locally advanced or metastatic breast cancer<\/strong> patients previously treated with endocrine therapy.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>11\u202fDec\u202f2025<\/td><\/tr>
Product<\/strong><\/td>Culmerciclib Capsules (oral)<\/td><\/tr>
Company<\/strong><\/td>Sino Biopharmaceutical (1177.HK)<\/td><\/tr>
Indication<\/strong><\/td>HR+\/HER2\u2011 locally advanced or metastatic breast cancer (post\u2011endocrine therapy)<\/td><\/tr>
Combination<\/strong><\/td>With fulvestrant injection<\/td><\/tr>
Innovation<\/strong><\/td>World\u2019s first CDK2\/4\/6 inhibitor<\/strong> (self\u2011developed Category\u202f1 drug)<\/td><\/tr>
Launch Timeline<\/strong><\/td>Q1\u202f2026 (hospital channel)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>Culmerciclib<\/th>Competitive Context<\/th><\/tr><\/thead>
Targets<\/strong><\/td>CDK2, CDK4, CDK6 kinases<\/td>Expands beyond CDK4\/6 class (palbociclib, ribociclib, abemaciclib)<\/td><\/tr>
Selectivity<\/strong><\/td>Strong preferential inhibition of CDK4<\/strong><\/td>Designed to delay resistance to existing CDK4\/6 inhibitors<\/td><\/tr>
Advantage<\/strong><\/td>Expected to alleviate bone marrow suppression<\/strong> vs. current agents<\/td>Addresses key toxicity limiting long\u2011term use<\/td><\/tr>
Administration<\/strong><\/td>Oral capsules, QD dosing<\/td>Patient\u2011convenient; aligns with endocrine therapy schedule<\/td><\/tr>
Second Filing<\/strong><\/td>Marketing application submitted July\u202f2025<\/strong> for initial endocrine treatment<\/strong> setting<\/td>Broader label expansion pending<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 CULMINATE\u20112 Study (ESMO\u202f2025)<\/h2>\n\n\n\n
Endpoint<\/th>Culmerciclib\u202f+\u202fFulvestrant<\/th>Placebo\u202f+\u202fFulvestrant<\/th>Statistical Significance<\/th><\/tr><\/thead>
Median PFS (mPFS)<\/strong><\/td>Not Reached (NR)<\/strong><\/td>20.2\u202fmonths<\/td>HR\u202f=\u202f0.56, p\u202f=\u202f0.0004<\/strong><\/td><\/tr>
Risk Reduction<\/strong><\/td>44% reduction<\/strong> in disease progression\/death<\/td>\u2014<\/td>Highly significant<\/td><\/tr>
Objective Response Rate (ORR)<\/strong><\/td>59.3%<\/strong><\/td>42.3%<\/td>p\u202f=\u202f0.0009<\/td><\/tr>
High\u2011Risk Subgroups<\/strong><\/td>Significant PFS benefit in visceral metastasis<\/strong> and liver metastasis<\/strong><\/td>\u2014<\/td>Demonstrates efficacy in hard\u2011to\u2011treat populations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Implication<\/th><\/tr><\/thead>
China HR+\/HER2\u2011 Breast Cancer Patients<\/strong><\/td>~\u202f150,000 annually (new + recurrent)<\/td>~60% receive endocrine therapy; 30\u201140% develop resistance<\/td><\/tr>
China CDK4\/6 Inhibitor Market<\/strong><\/td>\u00a58\u201110\u202fbillion<\/strong> (2025)<\/td>Dominated by imported agents; price pressure from NRDL<\/td><\/tr>
Culmerciclib Peak Sales Forecast<\/strong><\/td>\u00a53\u20114\u202fbillion<\/strong> (\u2248\u202fUS$420\u2011560\u202fM) by 2030<\/td>Captures 15\u201120% share with differentiation on safety and resistance profile<\/td><\/tr>
Reimbursement Strategy<\/strong><\/td>Target NRDL inclusion by 2027<\/strong> with 20\u201130% discount<\/strong> to imported CDK4\/6 inhibitors<\/td>Accelerates hospital adoption and patient access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n